PROTAC 工程化蛋白/DNA 纳米抗原是癌症免疫治疗中树突状细胞疫苗的有效增强剂
PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
增强癌症疫苗效力：基于 siRNA 的树突状细胞免疫抑制因子调控
英文原题：Enhancing Cancer Vaccine Efficacy: siRNA-Based Modulation of Immune Suppressive Factors in Dendritic Cells.
查看英文原题
Enhancing Cancer Vaccine Efficacy: siRNA-Based Modulation of Immune Suppressive Factors in Dendritic Cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
树突状细胞（DC）癌症疫苗已成为多种癌症患者的一种成熟治疗方式。然而，这种免疫疗法的治疗潜力往往受到负反馈机制的限制，这些机制通常防止免疫系统持续激活，从而降低自身免疫的风险。为克服这些挑战，新一代DC疫苗已利用RNA干扰（RNAi）技术开发，以抑制免疫抑制因子的表达，如吲哚胺2,3-双加氧酶1（IDO1）。所开发的疫苗有效刺激了T细胞，并在癌症患者中表现出抗肿瘤活性。本章描述了靶向IDO的siRNA的设计和酶促合成，以及在良好生产规范下将其纳入DC疫苗。
展开英文摘要原文
Dendritic cell (DC) cancer vaccines have become an established treatment modality for patients with a wide range of cancers.
However, the therapeutic potential of this immunotherapy is often limited by negative feedback mechanisms that normally prevent sustained activation of the immune system, thereby reducing the risk of autoimmunity. To overcome these challenges, a new generation of DC vaccines have been developed using RNA interference (RNAi) technology to inhibit the expression of immunosuppressive factors, such as indoleamine 2,3-dioxygenase 1 (IDO1).
The developed vaccines effectively stimulated T cells and demonstrated anti-tumor activity in cancer patients. This chapter describes the design and enzymatic synthesis of siRNA targeting IDO, along with its incorporation into DC vaccines under Good Manufacturing Practice.
论文信息
- 作者
- Sæbøe-Larssen S、Sioud M
- 第一作者单位
- Section for Cellular Therapy, Department of Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway.Norway
- 通讯作者单位
- Division of Cancer Medicine, Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. mosioud@medisin.uio.no.Norway
- 期刊
- Methods in molecular biology (Clifton, N.J.)2025
- 原文标识
- PubMed 40877509 · DOI 10.1007/978-1-0716-4742-4_12